Project: Recovery of high value Proteins from Serum by innovative direct Capture techniques
The extraction of biopharmaceuticals from natural sources often employs overly complicated antiquated procedures. The downstream processing of serum is a case in point; it comprises large numbers of steps of low purification power and consequently delivers poor overall product yields. Parallel advances in magnetic separation equipment and approaches to manufacture magnetic affinity particles, funded through several national and EU funded projects lay the foundations for the proposed work. Using magnetic bioseparation techniques, the consortium will seek to replace outdated organic solvent based fractionation methods, which can inflict serious damage on especially prone protein targets. In ProSeCa, our combined expertise will be applied to the production of protein based veterinary medicines from horse sera, centring on harmonious integrated use of: highly selective magnetic adsorbents manufactured via: (i) chemical; (ii) biological; and (iii) mixed ‘biological/chemical’ routes; with a fully automated and cGMP compliant magnetic separator.
| Acronym | ProSeCa |
| Website | visit project website |
| Network | ERA-IB-2 |
| Call | 4th ERA-IB Joint Call |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| Forschungszentrum für Medizintechnik und Biotechnologie fzmb GmbH | Germany | ||
| Karlsruhe Institute of Technology | Coordinator | Germany | |
| Senova GmbH | Germany | ||
| Technical University of DK | Denmark | ||
| University of Birmingham | United Kingdom |